Regular Article CLINICAL TRIALS AND OBSERVATIONS Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL
نویسندگان
چکیده
Department of Hematology, University Hospital Ghent, Ghent, Belgium; Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russian Federation; N.N. Blokhin Cancer Research Center, Russian Academy of National Sciences, Moscow, Russian Federation; National Cancer Center, Goyang Gyeonggi, Republic of Korea; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany; Servicio de Hematologia, Santa Maria Hospital, Lisbon, Portugal; Medical Scientific Radiology Center, Obninsk, Russian Federation; Janssen Research & Development, LLC, Raritan, NJ; Janssen Research & Development, LLC, Spring House, PA; Janssen Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium; and Department of Internal Medicine, Division of Hematology, Koc University, Istanbul, Turkey
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
Approximately 60% of patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) are curable with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemoimmunotherapy. Epratuzumab (E) is an unlabeled anti-CD22 monoclonal antibody with efficacy in relapsed DLBCL. This phase 2 trial tested the safety and efficacy of combining E with R-CHOP (ER-CHOP) in untreated...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
We evaluated the role of rituximab (R) both in remission induction and maintenance treatment of relapsed/resistant follicular lymphoma (FL). A total of 465 patients were randomized to induction with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (every 3 weeks) or R-CHOP (R: 375 mg/m2 intravenously, day 1). Those in complete remission (CR) or partial remission (PR...
متن کاملCLINICAL TRIALS AND OBSERVATIONS The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma
This is a phase 2 study to assess the role of tumor histogenesis (subtype), fluorodeoxyglucose positron emission tomography (FDG-PET), and short-course etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with dosedense rituximab (SC-EPOCH-RR) in newly diagnosed HIV-associated CD20 diffuse large B-cell lymphoma. Patients received a minimum of 3 and a maximum of 6 cycles with 1 ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
One thousand two hundred twenty-two patients treated in the Rituximab with CHOP over age 60 years (RICOVER-60) trial were examined for central nervous system (CNS) disease developing during first-line therapy or after a complete or partial remission had been achieved. Patients received 6 or 8 courses of CHOP (cyclophosphamide, adriamycin, vincristine, prednisone) administered every 2 weeks (CHO...
متن کاملCLINICAL TRIALS AND OBSERVATIONS The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity, with patients exhibiting a wide range of outcomes. The addition of rituximab to CHOP chemotherapy (R-CHOP)has led to a marked improvement in survival and has called into question the significance of previously recognized prognostic markers. Since randomized controlled trials of R-CHOP in DLBCL have included select subgroups of pat...
متن کامل